Solstice Oncology
A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment.
$225MSeries A
ParticipantCP
Canaan Partners
Activity from announced rounds
Activity in this selectionOct 17, 2026 · Jul 20, 2026
Canaan Partners is an investment firm whose company directory identifies Draig Therapeutics and Solstice Oncology.
Recorded funding activity
Draig develops neuropsychiatric medicines, while Solstice advances an engineered CTLA-4 antibody for cancer treatment. The recorded history also includes Actualyze AI’s enterprise gateway for model access, request security, budgets and routing. Named regional funds retain separate identities.
Sources
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $232M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionActualyze AI
An enterprise gateway for AI-model access, request security, budgets and routing.
$7MSeed
Role not disclosed